Best Myopia Treatments Ranked by What Actually Works
2026 Evidence-Based Guide
Short answer: The strongest myopia-control choices are not ranked by one number alone. Spectacle lenslets, dual-focus soft contacts, orthokeratology, and low-dose atropine all have evidence, but the right interpretation depends on age, baseline myopia, axial length, follow-up duration, adherence, country availability, and whether the study population resembles the child in front of you.
All treatment options ranked by efficacy
| Treatment | AL reduction vs untreated | Key trial | Min age / notes |
|---|---|---|---|
| Combination therapy † | ~68% (modeled) | Multiplicative model | Any age; stacks two modalities |
| Stellest® HAL lenses | ~67% at 2 years | Bao et al. 2022 | School age; worn ≥12hr/day |
| Atropine 0.05% | ~58% at 3 years | LAMP (Yam et al. 2019) | Any age; compounded drops |
| MiSight® 1 day | ~55% at 3 years | Chamberlain et al. 2019 | FDA-approved age 8–12 |
| MiyoSmart® DIMS | ~52% at 2 years | Lam et al. 2020 | School age; spectacle lenses |
| Orthokeratology | ~50% (meta-analysis) | Multiple RCTs | From ~age 7; overnight lenses |
| Atropine 0.025% | ~45% at 2 years | LAMP (Yam et al. 2019) | Any age; compounded drops |
| Atropine 0.01% | ~30% at 2 years | ATOM2 (Chia et al. 2012) | Any age; fewest side effects |
| Outdoor time (≥2hr/day) | ~18% onset reduction | Wu et al. 2018 | All ages; less effect once established |
† Combination therapy efficacy is a modeled composite (multiplicative, capped at 75%). No single RCT directly validates a specific combination at these figures. Efficacy values represent change in axial elongation vs untreated control at ~2-year endpoints. Individual outcomes vary. Treatment availability and regulatory approval vary by country.
Do not compare treatments by efficacy percentage alone
A 50–60% efficacy value can mean different things depending on the trial design. MyopiaTracker should treat every evidence claim as a structured clinical context, not a single headline number.
| Evidence field | Why it matters |
|---|---|
| Age range | A result in children aged 6–12 should not automatically be applied to preschoolers or young adults. |
| Baseline SER / AL | Mild, moderate, and high-myopia cohorts may respond differently. |
| Endpoint | Axial length, cycloplegic SER, adherence, rebound, and discontinuation answer different clinical questions. |
| Study duration | Short-term biometric signals are hypothesis-generating; multi-year follow-up is stronger for treatment planning. |
| Regulatory geography | A product available internationally may not be approved or indicated the same way in the United States. |
Choosing the right treatment
Under age 8 — or contact lens not suitable
Stellest® or MiyoSmart® spectacle lenses, or atropine 0.01–0.025% drops. No contact fitting required. Atropine can be added to spectacle lenses for additive effect.
Age 8–12, moderate progression
MiSight® (FDA-approved) or Stellest® are the leading options. MiSight requires daily contact lens handling; Stellest requires wearing the lenses ≥12 hours per day for full effect.
Fast progression at any age
Combination therapy — typically orthokeratology or MiSight® plus atropine. Produces the highest achievable efficacy. Consider if single-modality treatment is insufficient.
Prefers no daytime lenses
Orthokeratology — worn only overnight, providing glasses-free daytime vision. Requires nightly lens care and fitting by an experienced OD.
What about LASIK?
LASIK corrects vision but does not slow progression or reduce axial length. It is not a myopia management treatment and is generally recommended only after myopia has stabilised (typically not before age 21). See Is LASIK safe for myopia?
When to start
The IMI 2025 consensus: at diagnosis, not when progression becomes "fast enough." Every year of fast progression without intervention is permanently added to lifetime axial length and cannot be recovered.
See projected outcomes for your child's data
Enter age and axial length measurements. Get all 9 treatment modalities projected to age 18 — side by side — based on your child's actual growth rate.
Compare all treatments →Free · No login · Under 30 seconds
This page is for educational purposes and does not constitute medical advice. MyopiaTracker is a decision-support tool — not a diagnostic device. MiSight® is a registered trademark of The Cooper Companies. Stellest® is a registered trademark of Essilor International. MiyoSmart® is a registered trademark of Hoya Corporation. Treatment availability and regulatory approval vary by country. Consult a qualified optometrist or ophthalmologist for personalised advice.